Navigation Links
Enzymatics Reports Latest Growth Figures; Confirms Massachusetts' Emerging Role as Leading Bio-manufacturing Center

BEVERLY, Mass., June 9, 2011 /PRNewswire/ -- Enzymatics, Inc. announced today that the company, whose revenues have doubled every year since 2007, is forecasting triple the revenue in 2011 over 2010 figures.  It is also expanding its corporate offices and manufacturing facility in Beverly, Massachusetts.  The move is one of several significant milestones for the five year-old, privately held firm that supplies biological reagents as well as bio-processing consulting services to the international scientific and healthcare markets.  It also demonstrates that Massachusetts is no longer just a biotech R&D nursery and is quickly becoming an international center for biotech manufacturing.

Enzymatics' proprietary manufacturing process produces commercial quantities of enzymes measurably superior in purity and consistency to those created in small batches for the research field — but at a much lower cost.  The timing couldn't be better as national and international bioscience and pharmaceutical companies rush to create genomic diagnostics and bio-ceutical drug therapies for mass-market distribution.  Reagents are critical components of these products and in Enzymatics, their manufacturers have found an ideal partner supplier that can scale up to meet large production levels while exceeding purity standards and keeping costs down.  

"Our growth and expansion are a great confirmation that we had the right vision at exactly the right time," states Enzymatics Co-Founder and President Chris Benoit.  "It's been an incredible ride that's about to get even more exciting as we expand our presence in larger, international markets."  The company is currently establishing its first full-service overseas office in Europe. Enzymatics now supports a full time staff of more than 50 and is actively looking to fill an additional 15 positions.  

When asked to share his own perspective on the company's progress, Co-Founder and CEO Stephen Picone replied, "You can sense the future here...We're perfecting new manufacturing technologies built on our core competencies.  And the key collaborations we're setting up will lay the groundwork for the development of novel enzymes.  Both of these initiatives will add a great deal of value to our customer's businesses."

ABOUT ENZYMATICS:  Enzymatics is a leading biotechnology and biosciences manufacturing company that delivers ISO 13485-compliant enzymes of unrivaled purity, consistency, and value to the healthcare and bioscience industries.  For more information, please visit

Lisa Lazarczyk
781-646-0667 or

SOURCE Enzymatics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales
2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
3. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4. Cyberonics Reports Record Fiscal 2011 Results and Provides Fiscal 2012 Guidance
5. China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results
6. Encision Reports Profitable Fourth Quarter and Fiscal Year 2011 Results
7. Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011
8. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
9. China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results
10. Reports 82% Quarter-Over-Quarter Revenue Growth in the First Quarter 2011
11. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
Post Your Comments:
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
Breaking Medicine News(10 mins):